Immunomodulatory peptides and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10550171-B2
Application number	US-201314443630-A
Country	US
Kind code	B2
Filing date	Nov 21, 2013
Priority date	Nov 21, 2012
Publication date	Feb 4, 2020
Grant date	Feb 4, 2020

Abstract

The present disclosure provides peptides that modulate an immune response in an individual. The present disclosure provides peptides that modulate cellular responses in vitro. The present disclosure provides compositions comprising the peptides. The peptides and compositions are useful in methods of modulating an immune response in an individual, which methods are also provided.

First claim

What is claimed is:

1. A composition comprising:
an isolated peptide that comprises an amino acid sequence selected from:
a) LLKDCKCRSRLFPRTWDLRQ (SEQ ID NO:18);
b) LLKDCRCHSRLFPRTWDLRQ (SEQ ID NO:19); and
c) KLKNWSCSSPVFPGNWDLRL (SEQ ID NO:20),
wherein the isolated peptide modulates an immune response to an influenza virus in an individual, and wherein the isolated peptide has a length of 20 amino acids; and

an immune-stimulating amount of an adjuvant.

2. The composition of claim 1 , wherein the peptide comprises a non-peptide isosteric linkage.

3. The composition of claim 1 , wherein the peptide comprises at least one non-encoded amino acid.

4. The composition of claim 3 , wherein the non-encoded amino acid is a D-amino acid.

5. The composition of claim 1 , further comprising a pathogen or a pathogen component.

6. The composition of claim 5 , wherein the pathogen is a live attenuated virus, an inactivated virus, a split virus, a virus subunit, or a nucleic acid comprising a nucleotide sequence encoding a virus subunit.

7. The composition of claim 6 , wherein the virus is an influenza virus.

8. The composition of claim 6 , wherein the virus is a member of Herpesviridae.

9. A method of increasing an immune response in an individual, the method comprising administering to an individual in need thereof an effective amount of a composition of claim 1 .

10. The method of claim 9 , wherein the individual is a human.

11. The method of claim 10 , wherein the individual is immunocompromised.

12. The method of claim 9 , wherein said administering is via intramuscular injection, intradermal injection, subcutaneous injection, or via inhalation.

13. A method of modulating a cellular response in vitro or ex vivo, the method comprising contacting a cell or a cell population in vitro or ex vivo with a composition of claim 1 , wherein said contacting modulates a cellular response.

14. The method of claim 13 , wherein the cellular response comprises proliferation, cytokine production, or immunoglobulin production.

15. A method of modulating an immune response in an individual, the method comprising administering to an individual in need thereof an effective amount of a composition of claim 1 that inhibits binding of an IFN-λ polypeptide to an IL-28R.

Assignees

• Univ Alberta

Inventors

• Egli Adrian
• Santer Deanna Michelle
• Levin Aviad Yaagov
• Thomas Bradley Scott
• Barakat Khaled Hassan Sayed
• Joyce Michael A
• O'Shea Daire Thomas
• Bhat Rakesh Kumar
• Houghton Michael
• Tyrrell D Lorne J
• Humar Atul
• Kumar Deepali

Classifications

• C07K14/555

  Interferons [IFN] · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K2039/55516

  Proteins; Peptides · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title